Clinical review 15: Management of ovulatory disorders with pulsatile gonadotropin-releasing hormone.

摘要: The newest form of therapy for ovulation induction, iv pulsatile GnRH, (Lutrepulse, Ortho Pharmaceuticals, Raritan, NJ) was recently approved by the FDA use in women with primary amenorrhea. Numerous early attempts employing prolonged infusions or infrequent boluses GnRH to induce failed, and it thus initially appeared that exogenous treatment might be limited usefulness anovulatory disorders. However, soon after recognition episodic secretion gonadotropins from anterior pituitary gland a direct reflection antecedent endogenous hypothalamus, demonstration absolute requirement gonadotroph administration nature, therapeutic applications these principles began (1–3). Pulsatile given at frequency which approximates during follicular phase normal women, proved capable ripening follicle a...